Val66Met polymorphism and BDNF levels in Alzheimer's disease patients in North Indian population

International Journal of Neuroscience

Volumn 123, Issue 6, 2013, Pages 409-416

  Sonali, Nirmal ^a   Tripathi, Manjari ^b   Sagar, Rajesh ^a   Vivekanandhan, Subbiah ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Department of Neurology ^*  (India)

Author keywords

Alzheimer's disease; Amnestic mild cognitive impairment; BDNF; North India; Val66Met polymorphism

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITION; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; ALLELES; ALZHEIMER DISEASE; AMNESIA; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84878044581     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.762515     Document Type: Article

References (42)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosisof Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health andHuman Services Task Force on Alzheimer's Disease. Neurology1984;34(7):939-44.
2. Braak H, Braak E. Neuropathological stageing of Alzheimerrelatedchanges. Acta Neuropathol 1991;82(4):239-59.
3. Combarros O, Infante J, Llorca J, et al. Polymorphism at codon66 of the brain-derived neurotrophic factor gene is not associatedwith sporadic Alzheimer's disease. Dement Geriatr CognDisord 2004;18(1):55-8.
4. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitiveimpairment-beyond controversies, towards a consensus: reportof the International Working Group on Mild Cognitive Impairment.J Intern Med 2004;256(3):240-6.
5. Petersen RC. Mild cognitive impairment as a diagnostic entity.J Intern Med 2004;256(3):183-94.
6. Tapia-Arancibia L, Aliaga E, Silhol M, et al. New insights intobrain BDNF function in normal aging and Alzheimer disease.Brain Res Rev 2008;59(1):201-20.
7. Schindowski K, Belarbi K, Buee L. Neurotrophic factors inAlzheimer's disease: role of axonal transport. Genes Brain Behav2008;7(Suppl 1):43-56.
8. Kukull WA, Higdon R, Bowen JD, et al. Dementia andAlzheimer disease incidence: a prospective cohort study. ArchNeurol 2002;59(11):1737-46.
9. MurerMG, Boissiere F, Yan Q, et al. An immunohistochemicalstudy of the distribution of brain-derived neurotrophic factor inthe adult human brain, with particular reference to Alzheimer'sdisease. Neuroscience 1999;88(4):1015-32.
10. Murer MG, Yan Q, Raisman-Vozari R. Brain-derivedneurotrophic factor in the control human brain, and inAlzheimer's disease and Parkinson's disease. Prog Neurobiol2001;63(1):71-124.
11. Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotectiveeffects of brain-derived neurotrophic factor in rodentand primate models of Alzheimer's disease. Nat Med2009;15(3):331-7.
12. Peng S, Wuu J, Mufson EJ, et al. Precursor form of brainderivedneurotrophic factor and mature brain-derived neurotrophicfactor are decreased in the pre-clinical stages ofAlzheimer's disease. J Neurochem 2005;93(6):1412-21.
13. Holsinger RM, Schnarr J, Henry P, et al. Quantitationof BDNF mRNA in human parietal cortex by competitivereverse transcription-polymerase chain reaction: decreasedlevels in Alzheimer's disease. Brain Res Mol Brain Res2000;76(2):347-54.
14. Connor B, Young D, Yan Q, et al. Brain-derived neurotrophicfactor is reduced in Alzheimer's disease. Brain research. MolBrain Res 1997;49(1-2):71-81.
15. Laske C, Stellos K, Hoffmann N, et al. Higher BDNFserum levels predict slower cognitive decline in Alzheimer'sdisease patients. Int J Neuropsychopharmacol 2011;14(3):399-404.
16. Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNFserum concentrations in Alzheimer's disease. J Neural Transm2006;113(9):1217-24.
17. Yu H, Zhang Z, Shi Y, et al. Association study of the decreasedserumBDNF concentrations in amnestic mild cognitive impairmentand the Val66Met polymorphism in Chinese Han. J ClinPsychiatry 2008;69(7):1104-11.
18. O'Bryant SE, Hobson V, Hall JR, et al. Brain-derived neurotrophicfactor levels in Alzheimer's disease. J Alzheimers Dis2009;17(2):337-41.
19. Maisonpierre PC, Le Beau MM, Espinosa R III, et al. Humanand rat brain-derived neurotrophic factor and neurotrophin-3:gene structures, distributions, and chromosomal localizations.Genomics 1991;10(3):558-68.
20. Ventriglia M, Bocchio Chiavetto L, Benussi L, et al. Associationbetween the BDNF 196 A/G polymorphism and sporadicAlzheimer's disease. Mol Psychiatry 2002;7(2):136-7.
21. Leyhe T, Stransky E, Eschweiler GW, et al. Increase of BDNFserum concentration during donepezil treatment of patientswith early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci2008;258(2):124-8.
22. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." Apractical method for grading the cognitive state of patients forthe clinician. J Psychiatr Res 1975;12(3):189-98.
23. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale forthe staging of dementia. Br J Psychiatry (the journal of mentalscience). 1982;140:566-72.
24. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment:clinical characterization and outcome. Arch Neurol1999;56(3):303-8.
25. Carlesimo GA, Caltagirone C, Gainotti G. The Mental DeteriorationBattery: normative data, diagnostic reliability and qualitativeanalyses of cognitive impairment. TheGroup for the Standardizationof the Mental Deterioration Battery. Eur Neurol1996;36(6):378-84.
26. Shimizu E, Hashimoto K, Iyo M. Ethnic difference of theBDNF 196G/A (val66met) polymorphism frequencies: the possibilityto explain ethnic mental traits. Am JMed Genet B NeuropsychiatrGenet (the official publication of the InternationalSociety of Psychiatric Genetics) 2004;126B(1):122-3.
27. Pivac N, Nikolac M, Nedic G, et al. Brain derived neurotrophicfactor Val66Met polymorphism and psychotic symptoms inAlzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry2011;35(2):356-62.
28. Angelucci F, Spalletta G, di Iulio F, et al. Alzheimer's disease(AD) and mild cognitive impairment (MCI) patients are characterizedby increased BDNF serum levels. Curr Alzheimer Res2010;7(1):15-20.
29. Durany N, Michel T, Kurt J, et al. Brain-derived neurotrophicfactor and neurotrophin-3 levels in Alzheimer's disease brains.Int J Dev Neurosci 2000;18(8):807-13.
30. Marmigere F, Choby C, Rage F, et al. Rapid stimulatory effectsof brain-derived neurotrophic factor and neurotrophin-3 on somatostatin release and intracellular calcium risein primary hypothalamic cell cultures. Neuroendocrinology2001;74(1):43-54.
31. Villuendas G, Sanchez-Franco F, Palacios N, et al. Involvementof VIP on BDNF-induced somatostatin gene expression in culturedfetal rat cerebral cortical cells. Brain research. Mol BrainRes 2001;94(1-2):59-66.
32. Foulstone EJ, Tavare JM, Gunn-Moore FJ. Sustained phosphorylationand activation of protein kinase B correlates with brainderivedneurotrophic factor and insulin stimulated survival ofcerebellar granule cells. Neurosci Lett 1999;264(1-3):125-8.
33. Leroy K, Boutajangout A, Authelet M, et al. The active formof glycogen synthase kinase-3beta is associated with granulovacuolardegeneration in neurons in Alzheimer's disease. ActaNeuropathol 2002;103(2):91-9.
34. Schmidt HD, Duman RS. The role of neurotrophic factors inadult hippocampal neurogenesis, antidepressant treatments andanimal models of depressive-like behavior. Behav Pharmacol2007;18(5-6):391-418.
35. Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophicfactor and its receptor tropomyosin-related kinase B inthemechanism of action of antidepressant therapies. PharmacolTher 2008;117(1):30-51.
36. Ferrer I, Marin C, Rey MJ, et al. BDNF and full-lengthand truncated TrkB expression in Alzheimer disease. Implicationsin therapeutic strategies. J Neuropathol Exp Neurol1999;58(7):729-39.
37. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophicfactor, depression, and antidepressant medications:meta-analyses and implications. Biol Psychiatry2008;64(6):527-32.
38. Nagata T, Shinagawa S, Nukariya K, et al. Associationbetween brain-derived neurotrophic factor (BDNF) genepolymorphisms and executive function in Japanese patientswith Alzheimer's disease. Psychogeriatrics 2011;11(3):141-9.
39. Zhang L, Fang Y, Zeng Z, et al. BDNF gene polymorphismsare associated with Alzheimer's disease-related depressionand antidepressant response. J Alzheimers Dis 2011;26(3):523-30.
40. Diniz BS, Teixeira AL. Brain-derived neurotrophic factor andAlzheimer's disease: physiopathology and beyond. NeuromolecularMed 2011;13(4):217-22.
41. O'Bryant SE, Hobson VL, Hall JR, et al. Serum brain-derivedneurotrophic factor levels are specifically associated with memoryperformance among Alzheimer's disease cases. DementGeriatr Cogn Disord 2011;31(1):31-6.
42. Ziegenhorn AA, Schulte-Herbruggen O, Danker-Hopfe H,et al. Serum neurotrophins-a study on the time course andinfluencing factors in a large old age sample. Neurobiol Aging2007;28(9):1436-45.